Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 15/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18199497 | 0.90 | RAB9A (0.49) | SMYD3RAB9ACYP3A4HPGDCYP2C19 | |
| SCHEMBL5067337 | 0.90 | RAB9A (0.49) | SMYD3RAB9ACYP3A4HPGDCYP2C19 | |
| SCHEMBL21490018 | 0.84 | SMYD3 (0.49) | SMYD3RAB9ACYP3A4HPGDCYP2C19 | |
| SCHEMBL19701247 | 0.84 | SMYD3 (0.49) | SMYD3RAB9ACYP3A4HPGDCYP2C19 | |
| SCHEMBL15014614 | 0.83 | EPHX1 (0.48) | RAB9ACYP3A4HPGDCYP2C19EPHX1 | |
| SCHEMBL15014593 | 0.83 | EPHX1 (0.48) | RAB9ACYP3A4HPGDCYP2C19EPHX1 | |
| SCHEMBL11890370 | 0.82 | RAB9A (0.54) | RAB9ACYP3A4HPGDCYP2C19EPHX1 | |
| SCHEMBL11890375 | 0.82 | RAB9A (0.58) | RAB9ACYP3A4HPGDCYP2C19EPHX1 | |
| SCHEMBL12384535 | 0.81 | RAB9A (0.43) | SMYD3RAB9ACYP3A4HPGDCYP2C19 | |
| SCHEMBL8241745 | 0.81 | EPHX1 (0.58) | RAB9ACYP3A4HPGDCYP2C19EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019492-B1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INT (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-9126982-B2 | Heterocyclic compounds, medicaments containing them, use and processes for the preparation thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-08 | — | — | US | disclosed |
| WO-2015003958-A1 | AMILORIDE-TYPE COMPOUNDS AS INHIBITORS IN EPITHELIAL SODIUM CHANNELS FOR THE TREATMENT OF DISEASES OF THE LUNGS AND AIRWAYS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-15 | — | — | WO | disclosed |
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011535-A1 | HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING THEM, USE AND PROCESSES FOR THE PREPARATION THEREOF | SCNN1B, SCNN1A, TRPM5 | SMYD3 4130/4885RAB9A 4077/4885CYP3A4 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.